Quazepam

Clinical contraindication: None listed; No clinical contraindication identified.
Best available evidence: Standard practice
Half-life: 39 h; Approximate, in adults. Detail in 01.

Named in state rules?

CONot named

ORNot named

NMPending

Cite asPsilodex: quazepam · v2026.10.02

Clinical data and state rules are separate facts. Both are shown; neither is a decision.

01 Interaction with psilocybin

Blunting; long half-life means next-day carryover; withdrawal seizures if abrupt.

Human data with psilocybin: None known: no published human data with psilocybin
Common practice: Daily use carries withdrawal risk if stopped abruptly. Any change is the prescriber's decision.
Half-life: quazepam + 2-oxoquazepam mean 39 h / N-desalkyl-2-oxoquazepam 73 h (FDA label, checked 2026-09-30)

Evidence types on this record

PrStandard practice; no psilocybin-specific data

2 listed · counted on reports

Sedating or CNS depressant: Slows the central nervous system: drowsiness, slower reactions and impaired coordination, and slowed breathing at high doses. Effects add with other sedating substances. Sources [1]
Withdrawal or rebound if stopped abruptly: Stopping suddenly can cause withdrawal or a rebound of symptoms. Any change to the dose is the prescriber’s decision. Sources [1]

Official text governs

CO4 CCR 755-1

Not named

No provision names this medication or its class.

Colorado · checked 2026-09-30

OROAR 333-333

Not named

No provision names this medication or its class.

Oregon · checked 2026-09-30

NM7.35.3 NMAC (proposed)

Pending

New Mexico's clinical rules (proposed 7.35.3 NMAC) are not final. No provision naming this medication has been found.

New Mexico · checked 2026-09-30

None linked

No condition named in state rules is linked to this medication.